Morgan Stanley and Scotiabank cut DT Midstream price target to $161
Morgan Stanley and Scotiabank kept positive ratings on DT Midstream but lowered their price targets to $161 a share, according to TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Morgan Stanley kept its Overweight rating on DT Midstream and cut its price target to $161 from $164, a decrease of 1.8%. Scotiabank kept its Sector Outperform rating and reduced its target to $161 from $165, a cut of 2.4%. According to TradingView, both updates were published on November 3.
The outlet says the new targets imply upside of about 33.1% from the November 2 close of $120.98. The data is provided by Benzinga. In the same feed, price targets across the three most recent analyst notes over the past 30 days ranged from $142 to $167.
why it matters
Revisions like these are routine for analyst coverage and usually reflect small model adjustments rather than new company news. Both firms still rate the stock positively, so the cuts mainly trim expected value rather than change the overall view. The source notes that the material is not investment advice.
tags
instruments
sources
- Morgan Stanley maintains DT Midstream at Overweight, lowers price target to $161 from $164 — TradingView, 3 November 2026 at 17:25 UTC
- Scotiabank maintains DT Midstream at Sector Outperform, lowers price target to $161 from $165 — TradingView, 3 November 2026 at 17:30 UTC
- Morgan Stanley maintains Vertex Pharmaceuticals at Overweight, lowers price target to $660 from $665 — TradingView, 3 November 2026 at 17:43 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗